Clinical responses seen with PD-1/PD-L1 inhibitors in tumors suggested potential benefits for sepsis IP (27, 29), and a phase 1 trial of nivolumab in patients with sepsis (n=31) demonstrated safety. The gene discussed is CD274; the disease is Sepsis.